BRAF and neuroblastoma: However, considering that this metabolic adaptation has been observed in both melanoma cells with different BRAF mutation and in etoposide resistant neuroblastoma cells (18), we believe that this response is neither cancer-type specific nor related to the specific drug-induced cytotoxic effect.